Summit Therapeutics: A High-Stakes Bet on Ivonescimab Amidst a Deepening Cash Crunch

Related Articles

Ouster's $200M Capital Raise: A High-Stakes Bet on Lidar's Future Amidst Persistent Cash Burn

1 months ago

What Do Summit Therapeutics' Q4 Results Reveal About Its Financial Health

5 months ago

Unusual Machines: A High-Stakes Bet on the U.S. Drone Boom's Promise

1 months ago

Eli Lilly's $2.8 Billion Psychedelic Bet: High Stakes in a Nascent Market

3 weeks ago

Category

You may also like

Stock News•2 weeks ago

Summit Therapeutics Flags Going Concern Risk Over Cash Needs

Summit Therapeutics flagged a going concern risk due to cash needs, despite reporting an adjusted loss of 19 cents per share, beating consensus estimates of a 28-cent loss.

SMMT

Share

Stock News•2 weeks ago

Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data

Summit Therapeutics was upgraded to 'Buy' after FDA accepted its BLA for ivonescimab in EGFR-mutant NSCLC. OS hazard ratios improved to 0.76 in HARMONi trial. Akeso's HARMONi-6 showed a 34% risk reduc...

SMMT

Share

Stock News•1 months ago

Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment

Sionna Therapeutics' NBD1 stabilization approach could enhance CFTR function beyond current CF standards. SION-719 and SION-451 face pivotal readouts in summer 2026. A $289.9M cash runway through 2028...

SION

Share

Stock News•2 months ago

Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1

Replimune Group faces a critical liquidity crunch with less than one year of cash remaining. The company is currently evaluating workforce reductions and the potential discontinuation of its RP1 progr...

REPL

Share